The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

The FDA has categorized this as a Class I recall, which means using the devices “may cause serious injuries or death.”

Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.

Anjali Owens, MD, discussed the past, present and future of hypertrophic cardiomyopathy care in the United States. "What we are aiming to do is develop a minimum standard for assessments of patients with HCM so they are getting properly diagnosed and managed," she explained. 

The vascular surgeon was fired after telling the media about a cardiologist who allegedly performed transcatheter aortic valve replacement without the proper credentials. He is now suing the hospital for wrongful termination and defamation.

Early data suggest the new transcatheter tricuspid valve repair device could make a big impact on patient care, but additional research is still necessary. 

The group collaborated with two other medical societies, SCAI and CHSS, on the expert consensus document.